• Home
  • About OptiScan
    • About OptiScan
    • Leadership
    • Board of Directors
  • Clinical Results
    • Clinical Results
    • Clinical Benefits
  • Technology/Products
    • Technology/Products
    • OptiScanner 5000
    • FAQs
  • Careers
  • News and Events
  • Contact Us
  • Home
  • About OptiScan
    • About OptiScan
    • Leadership
    • Board of Directors
  • Clinical Results
    • Clinical Results
    • Clinical Benefits
  • Technology/Products
    • Technology/Products
    • OptiScanner 5000
    • FAQs
  • Careers
  • News and Events
  • Contact Us

Misc.

Home / Misc. /
By Cindy Cullen
In Misc., Press Releases
Posted October 18, 2017

OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU

OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU First-of-its-Kind Automated, [...]

Read More
RECENT RELEASES
  • OptiScan Biomedical Receives CE Mark for OptiScanner ® 7000 for Automated Multivariate Monitoring of Metabolic and Hemodynamic Status of Patients in the Intensive Care Unit
    May 12, 2020
  • OptiScan Biomedical Announces Peer-Reviewed Publications Highlighting First-of-its-Kind Continuous Monitoring Platform for Intensive Care Units
    December 7, 2019
  • OptiScan Biomedical Completes $20 Million Series E Financing
    March 20, 2019





Copyright ©2018 OptiScan. All Rights Reserved.